Biosecurity Modernization and Innovation Act of 2026

Strengthened National Security and Public Health: Section 4(a)(1) requires covered providers to implement screening protocols for sequences of concern, which helps mitigate the misuse of sequences capable of creating pathogens with pandemic potential. This protects everyday people from dangerous biological threats.

Reduced Red Tape for Trusted Institutions: Section 4(a)(6)(A) allows covered providers to offer an expedited review process for institutional customers, such as accredited universities, that have a demonstrated record of legitimacy. This provision ensures that important academic research is not slowed down by unnecessary regulatory burdens.

Technical Assistance for Providers: Section 4(a)(8) establishes a program to provide technical assistance upon the request of a covered provider, including help with orders that have ambiguous screening results. This support helps businesses comply with the law correctly without guessing.

Financial Penalties for Violations: Section 4(f)(3) makes individuals and organizations liable for steep statutory damages of up to $500,000 for individuals and $750,000 for non-individuals if they violate requirements or provide false information. These large fines could severely burden or bankrupt smaller businesses or individuals who make administrative mistakes.

Increased Regulatory Burdens on Businesses: Section 4(a)(5) creates a conformity assessment system that includes mandatory audits and random adversarial testing to ensure compliance. These strict oversight mechanisms could create extra operational hurdles and stress for companies operating in the biotechnology space.